These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30561264)

  • 1. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients.
    Ahmed O; Littmann K; Gustafsson U; Pramfalk C; Öörni K; Larsson L; Minniti ME; Sahlin S; Camejo G; Parini P; Eriksson M
    J Am Heart Assoc; 2018 Dec; 7(24):e009876. PubMed ID: 30561264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E;
    Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe + statin: insufficient benefit.
    Prescrire Int; 2016 Oct; 25(175):245-246. PubMed ID: 30645833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication Discontinuation in the IMPROVE-IT Trial.
    Navar AM; Roe MT; White JA; Cannon CP; Lokhnygina Y; Newby LK; Giugliano RP; Tershakovec AM; Braunwald E; Califf RM; Blazing MA
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e005041. PubMed ID: 30630361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe: rescued by randomization (clinical and mendelian).
    McPherson R; Hegele RA
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):e13-5. PubMed ID: 25550209
    [No Abstract]   [Full Text] [Related]  

  • 12. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
    Storey BC; Staplin N; Haynes R; Reith C; Emberson J; Herrington WG; Wheeler DC; Walker R; Fellström B; Wanner C; Landray MJ; Baigent C;
    Kidney Int; 2018 Apr; 93(4):1000-1007. PubMed ID: 29146277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
    Fazio S
    Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
    Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients.
    Ghanim H; Green K; Abuaysheh S; Patel R; Batra M; Chaudhuri A; Makdissi A; Kuhadiya ND; Dandona P
    Atherosclerosis; 2017 Aug; 263():278-286. PubMed ID: 28711708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
    Telford DE; Sutherland BG; Edwards JY; Andrews JD; Barrett PH; Huff MW
    J Lipid Res; 2007 Mar; 48(3):699-708. PubMed ID: 17130282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia.
    Dane-Stewart CA; Watts GF; Mamo JC; Barrett PH; Martins IJ; Dimmitt SB; Redgrave TG
    Eur J Clin Invest; 2002 Jul; 32(7):493-9. PubMed ID: 12153549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.